drug discovery

Pharmaceutical company Roche has outlined plans to move towards autonomous, AI-driven laboratories. According to a Reuters report, the Swiss drugmaker intends to use artificial intelligence and robotics to automate research workflows, accelerating drug discovery and reducing the need for manual lab work. The announcement highlights how major pharma firms are adopting AI to speed up experimentation and research.

Researchers have identified a new potential treatment target for high blood pressure, a condition affecting over a billion people worldwide and a leading risk factor for heart disease and stroke. The discovery could open the door to new drug development beyond existing blood pressure medications. Details of the findings and their clinical significance remain limited.

Anthropic has opened a new biology lab, a move widely read as a signal that the company's ambitions extend well beyond building artificial intelligence. The initiative suggests Anthropic wants to apply AI capabilities directly to biological research and drug discovery, positioning itself as a player in the life sciences rather than solely a model developer.

Insilico Medicine has signed a co-development deal worth tens of millions of dollars with an unnamed foundation-model laboratory, joining forces to apply large AI models to drug discovery. The Hong Kong-based biotech, known for using generative AI to design drug candidates, has not disclosed its partner or the exact terms, leaving observers speculating about which AI lab is behind the agreement.

Anthropic has established its own wet laboratory as it expands its AI-driven drug discovery programme, according to Reuters. The lab will let the company test biological hypotheses generated by its AI models in real experiments. Observers see it as a notable step for an AI firm moving from software into hands-on biology and pharmaceutical research.

Snorkel AI closed a $350 million Series E round led by Insight Partners on September 23, 2026, while biotech startup Enveda raised $311 million in its own Series E the same day. Neither company sells a chatbot, highlighting investor appetite for AI firms focused on data infrastructure and drug discovery rather than consumer chat products.

Drug Discovery News is asking why regulatory screening tends to happen only after a formulation or 'recipe' has already been completed. The piece explores why safety and compliance checks are positioned late in product development rather than earlier, a sequencing that can mean costly redesigns when problems surface. Readers in drug development and food science circles are debating whether earlier screening would save time and money.

Drug discovery researchers are being urged to move beyond simple endpoint measurements and gather richer data at the cellular level. The argument is that deeper, cell-based data quality—not simply larger datasets—will improve how promising medicines are identified and developed. The discussion highlights growing interest in high-content imaging and single-cell approaches in pharmaceutical research.

10x Genomics has started shipping its Atera spatial biology platform to customers. The system is designed to map gene activity within intact tissue, a growing area of interest for drug discovery and disease research. The company positions Atera as a step toward making whole-tissue, single-cell analysis more accessible to laboratories. Response from the research community has not yet been detailed.